Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 135

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 135
---
486 240 734 Loss (gain) on derivative instruments20,010 (250)— Gain on debt extinguishment— — (4,192)Non-cash income from financial royalty assets(5,467)(878)(164)CECL adjustment to financial royalty assets(4,315)3,595 — Impairment loss of financial royalty assets30,572 924 — Lease amortization expense2,126 1,735 5,521 Share-based compensation41,089 25,743 60,285 Losses from equity method investment in Primrose Bio12,821 1,829 — Fair value adjustment to Primrose Bio securities investments25,788 — — Deferred income taxes, net(15,800)11,696 20,723 Other7,723 739 365 Changes in operating assets and liabilities, net of acquisitions and dispositions:Accounts receivable, net(6,459)(2,601)55,319 Inventory9,619 (10,870)12,058 Other economic rights— (5,000)— Accounts payable and accrued liabilities13,903 (4,704)(3,340)Income taxes receivable and payable2,310 (1,781)1,579 Deferred revenue(1,308)419 (6,281)Other assets and liabilities1,291 (9,865)6,342 Net cash provided by operating activities97,047 49,577 137,850 Cash flows from investing activities:Acquisition of financial royalty assets(17,819)(50,328)— Proceeds from financial royalty assets7,429 418 92 Purchases of property and equipment(1,821)(3,521)(17,923)Purchases of short-term investments(226,384)(126,764)(51,226)Proceeds from sale of short-term investments229,367 148,765 209,561 Proceeds from maturity of short-term investments33,131 45,402 24,830 Cash paid for equity method investment - Nucorion— — (750)Cash paid for investment in Primrose Bio(998)(15,249)— Cash paid for Palvella notes receivable(2,500)— — Cash paid for Novan acquisition, net of restricted cash received— (10,405)— Cash paid